PT - JOURNAL ARTICLE AU - Shrestha, R AU - Katuwal, N AU - Tamrakar, D AU - Tato, CM AU - Vanaerschot, M AU - Ahyong, V AU - Gil, J AU - Madhup, SK AU - Gupta, BP AU - Jha, R TI - Investigation of acute encephalitis syndrome with implementation of metagenomic next generation sequencing in Nepal AID - 10.1101/2023.03.21.23286552 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.21.23286552 4099 - http://medrxiv.org/content/early/2023/12/05/2023.03.21.23286552.short 4100 - http://medrxiv.org/content/early/2023/12/05/2023.03.21.23286552.full AB - Background The causative agents of Acute Encephalitis Syndrome remain unknown in 68-75% of the cases. In Nepal, the cases are tested only for Japanese encephalitis, which constitutes only about 15% of the cases. However, there could be several organisms, including vaccine-preventable etiologies that cause acute encephalitis, when identified could direct public health efforts for prevention, including addressing gaps in vaccine coverage.Objectives This study employs metagenomic next-generation-sequencing in the exploration of infectious etiologies contributing to acute encephalitis syndrome in Nepal.Methods In this study, we investigated 90, Japanese-encephalitis-negative, banked cerebrospinal fluid samples that were collected as part of a national surveillance network in 2016 and 2017. Randomisation was done to include three age groups (<5-years; 5-14-years; >15-years). Only some metadata (age and gender) were available. The investigation was performed in two batches which included total nucleic-acid extraction, followed by individual library preparation (DNA and RNA) and sequencing on Illumina iSeq100. The genomic data were interpreted using Chan-Zuckerberg-ID and confirmed with polymerase-chain-reaction.Results Human-alphaherpesvirus-2 and Enterovirus-B were seen in two samples. These hits were confirmed by qPCR and semi-nested PCR respectively. Most of the other samples were marred by low abundance of pathogen, possible freeze-thaw cycles, lack of process controls and associated clinical metadata.Conclusion From this study, two documented causative agents were revealed through metagenomic next-generation-sequencing. Insufficiency of clinical metadata, process controls, low pathogen abundance and absence of standard procedures to collect and store samples in nucleic-acid protectants could have impeded the study and incorporated ambiguity while correlating the identified hits to infection. Therefore, there is need of standardized procedures for sample collection, inclusion of process controls and clinical metadata. Despite challenging conditions, this study highlights the usefulness of mNGS to investigate diseases with unknown etiologies and guide development of adequate clinical-management-algorithms and outbreak investigations in Nepal.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Bill and Melinda Gates Foundation under Grand Challenges.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was ethically cleared from Nepal Health Research Council (NHRC) under id: 903 - 2019.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the author. The pathogen genomic data can be found in Sequence Read Archive, National Center for Biotechnology Information (NCBI), under BioProject no PRJNA1019500.